GlaxoSmithKline has announced that its innovative heart drug darapladib has failed reduce heart attacks or other major cardiac events in patients suffering acute coronary syndrome.
This marks a further disappointment for the heart medicine that has previously failed to pass a late-stage trial for patients with well-treated heart disease.
GSK’s President of Pharmaceuticals R&D Patrick Vallance expressed his disappointment with the result of the second phase III study that did not support a regulatory submission.
The company’s statement declared that the drug darapladib did not achieve the desired primary endpoint of a reduction of major coronary events versus placebo when added to standard of care.
13 May 2014
Latest Articles
Heart, heart attack, heart disease, GSK, acute coronary syndrome, drug trails
GlaxoSmithKline has announced that its innovative heart drug darapladib has failed reduce heart attacks or other major cardiac events in patients suffering...
